Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Fintel reports that on December 22, 2025, HC Wainwright & Co. reiterated coverage of Ovid Therapeutics (NasdaqCM:OVID) with a Buy recommendation. Analyst Price Forecast Suggests 189.69% Upside As of ...

On December 11, Wedbush analyst Laura Chico maintained her bullish stance on Denali Therapeutics (NASDAQ:DNLI).

On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX).

Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...

As of Wednesday, December 17, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 29.30%, which has investors ...

Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...